Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study

First-line treatment with regorafenib in frail metastatic colorectal cancer (mCRC) patients has shown some benefit. To accurately identify such patients before treatment, we studied blood biomarkers and primary tumor molecules. We unveiled serum microRNAs (miRNAs), single-nucleotide polymorphisms (S...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2021-04, Vol.13 (7), p.1710
Hauptverfasser:	Conde, Elisa, Earl, Julie, Crespo-Toro, Lorena, Blanco-Agudo, Carolina, Ramos-Muñoz, Edurne, Rodríguez-Serrano, E Macarena, Martínez Ávila, Jose Carlos, Salinas-Muñoz, Laura, Serrano-Huertas, Silvia, Ferreiro, Reyes, Rodriguez-Garrote, Mercedes, Sainz, Jr, Bruno, Massuti, Bartomeu, Alfonso, Pilar García, Benavides, Manuel, Aranda, Enrique, García-Bermejo, María Laura, Carrato, Alfredo
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Asthenia Biomarkers Biopsy Cancer Cancer therapies Colorectal cancer Colorectal carcinoma Genotyping Homeostasis Kinases Metastases Metastasis MicroRNAs miRNA Notch1 protein Patients Peritoneum Serum levels Single-nucleotide polymorphism Toxicity Tumors Vascular endothelial growth factor Vascular endothelial growth factor receptors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!